Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
about
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapyIrinotecan pharmacogenomicsEvaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidinesReporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on IrinotecPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsGenetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsPolymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancerComet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivoPredictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancerGenetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology GroupFolate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea.Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicityBiomarker use in colorectal cancer therapy.Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based ChemotherapyUGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.Biomarker-based selection of therapy for colorectal cancer.Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism.DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
P2860
Q27851574-9372DFF3-C37A-4477-A5EC-CF194E47CF99Q28287024-08CC83CC-E5EC-4F84-9947-78BCC14D50B3Q28534572-3900AD79-6C7E-41A6-A72F-1242051AAC68Q30514241-0D1142F2-5B18-4BF6-B9DB-CE8E19CB0A12Q33418614-1F029DF2-9FC4-4C1A-9B62-1ED03AAB4ED1Q33747440-8EFAE9AD-90A9-4784-816A-AC9A1BE545F9Q33810014-15890AB3-B066-44BA-BC89-B9956DC28A29Q33823686-2F28D634-DD58-406D-850C-D70654FED0AEQ33875931-66E37318-DEB4-4E82-B6FC-7CD791ADD7FBQ34008793-12382994-FC2D-42A3-8999-0058F1C87955Q34452900-344B1C35-3310-4552-A8AB-D3681D81ED7CQ34653433-2890666B-03C1-43EC-8F8D-6B866C230EA3Q34682560-D72999FA-D986-4F89-8193-24BF5FE09F08Q35109800-8EA77BAC-6E18-4320-B58F-BE4476B92832Q35584977-87741A06-756B-4BE6-9CA9-4652C301013FQ35742555-24BED626-22BA-4E6A-A6C0-1A4CC78033FEQ36051757-3DC0DF52-FF1C-48A2-B5BC-DC2E508BC798Q36117701-6741CB41-6429-4FDC-9274-00C09A314F36Q36483179-68962D95-328F-46E3-B7CF-8E36BB86B3E4Q36584224-7FC04EE7-1E5B-47F3-85A6-EC0D0308E1B4Q36695209-1D736616-B71E-47F2-B87B-40B1E553D9EBQ36746734-606F77D4-C0AC-46F9-AAE9-318945563911Q36959145-28AEC83F-8E57-4D70-9F56-A95B7037ABCEQ36968539-81369C68-4FE3-48A5-8DD4-31E068617A85Q36993563-9EBDC9FC-B3F5-40C2-A4D7-62238324C7C5Q37402459-E8A436A6-EA07-4580-A88D-7D5EF51F26DFQ37682812-F863960E-C3BB-4534-8695-3DAF8587E902Q37712297-F29F3765-92F3-4C02-AAF1-E2CA112BE09CQ37886995-0C6591B3-999F-4FDA-A870-C6F04A5CC2B6Q37969770-0945F8B1-BF7E-4117-8E77-59A3C609B1A1Q37997047-19ACAE59-BB65-46FB-A3F1-C534814179C3Q38127715-00E801FB-FCB1-4DCF-836A-8922C22C1446Q38393997-6C7DA68A-92DA-4156-995E-688A7B1B4AA0Q38513661-0679FE93-3B86-48B3-80C1-1E869285F632Q38740840-40D83FC3-4614-4378-83F5-AD1253748149Q38827826-C63D74C4-DFC4-4A2D-A5A9-82EC8C56FFB7Q38835268-C3B8E0CC-2243-4882-AF62-749CAEC22B84Q38922471-6527951B-7103-4393-AC5F-C74E3B8E0F47Q39307013-F7DD1326-D1FC-44F3-AABD-B2322B7105A1Q39566084-CA392017-B64F-4549-9197-C702053F70C8
P2860
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en-gb
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@nl
type
label
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en-gb
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@nl
prefLabel
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en-gb
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@nl
P2093
P50
P356
P1476
Association of molecular marke ...... ectal cancer: the FOCUS trial.
@en
P2093
Angela M Meade
Catherine L Daly
James M Allan
Lindsay Thompson
Mahesh K B Parmar
Matthew T Seymour
Michael S Braun
P304
P356
10.1200/JCO.2008.21.6283
P407
P577
2009-10-26T00:00:00Z